Royalty Pharma Plc

( )
RPRX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.83%145.130.7%$900.66m
PFEPfizer Inc. 1.03%37.460.9%$772.03m
MRKMerck & Co., Inc. 1.45%79.200.7%$634.61m
BMYBristol-Myers Squibb Co. 1.22%60.761.0%$630.06m
ABBVAbbVie, Inc. 1.70%84.301.9%$601.86m
LLYEli Lilly & Co. 0.20%141.591.1%$484.74m
AZNAstraZeneca Plc 0.76%51.961.2%$203.71m
NVSNovartis AG 0.37%84.450.2%$142.55m
GSKGlaxoSmithKline Plc -0.74%35.090.2%$137.88m
NVONovo Nordisk A/S 0.06%70.890.1%$69.98m
RGENRepligen Corp. 2.77%176.517.1%$64.16m
RPRXRoyalty Pharma Plc 0.54%39.210.2%$64.00m
SNYSanofi -0.49%48.930.2%$49.73m
AMAGAMAG Pharmaceuticals, Inc. 0.22%13.6622.1%$45.13m
PRAXPraxis Precision Medicines, Inc. 6.95%32.000.0%$43.27m

Company Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.